Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Analysts See $-0.89 EPS on June, 15

May 17, 2018 - By Megan Stone

Earnings report for Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) is awaited on June, 15., as reported by Faxor. Analysts expect change of 48.85 % or $0.85 from previous year’s $-1.74 earnings per share compared to current’s $-0.89 earnings per share. Wall Street sees 18.67 % negative EPS growth as of June, 15. BHVN is hitting $29.95 during the last trading session, after increased 0.60%.Biohaven Pharmaceutical Holding Company Ltd. has volume of 453,190 shares. Since May 17, 2017 BHVN has 0.00% and is . BHVN underperformed the S&P 500 by 11.55%.

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders.The firm is worth $1.16 billion. The Company’s advanced product candidate includes rimegepant, which is intended to initiate two Phase III clinical trials for the acute treatment of migraine; and trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia.Last it reported negative earnings. The firm also develops BHV-3500 for the prevention of chronic and episodic migraine; BHV-0223 for the treatment of amyotrophic lateral sclerosis, a neurodegenerative disease that affects nerve cells in the brain and spinal cord; and BHV-5000 for the treatment of symptoms associated with Rett syndrome, such as breathing irregularities.

For more Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) news announced recently go to: Seekingalpha.com, Prnewswire.com, Seekingalpha.com, Prnewswire.com or Streetinsider.com. The titles are as follows: “Biohaven Pharma announces key milestones for 2018” announced on May 15, 2018, “Biohaven Pharmaceuticals Reports First Quarter 2018 Financial and Recent Business Results” on May 15, 2018, “Biohaven announces secondary endpoint results from Phase 3 clinical trials BHV3000-301 and 302 of Rimegepant” with a publish date: April 23, 2018, “Biohaven Initiates Expanded Access Program for Sublingual BHV-0223 ZYDIS® Orally Dissolving Tablets for Patients …” and the last “Biohaven (BHVN) to Present Additional Phase 3 Rimegepant Data at AAN 2018 on April 22nd” with publication date: April 19, 2018.

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: